NCT05962788 (VOCAL-EXT) is a Phase 3 clinical trial of voclosporin in Adolescent Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc..

Who is sponsoring NCT05962788?

NCT05962788 is sponsored by Aurinia Pharmaceuticals Inc..

What drugs are being tested in NCT05962788?

Interventions in NCT05962788: voclosporin.

What condition does NCT05962788 study?

NCT05962788 studies Adolescent Lupus Nephritis, Pediatric Lupus Nephritis.

Is NCT05962788 still recruiting?

NCT05962788 is currently terminated. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT05962788: VOCAL-EXT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

Terminated Phase 3 Last updated 10 February 2026

What this trial tests

Phase 3 trial testing voclosporin in Adolescent Lupus Nephritis in 4 participants. Terminated before completion.

Timeline

28 March 2024

Primary endpoint
4 July 2025

4 July 2025

Quick facts

Lead sponsor	Aurinia Pharmaceuticals Inc.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	28 March 2024
Primary completion	4 July 2025
Estimated completion	4 July 2025
Sites	6 locations across Colombia, Japan, Mexico, Thailand, United States

Drugs / interventions tested

voclosporin — full drug profile →

Conditions studied

Adolescent Lupus Nephritis — all drugs for Adolescent Lupus Nephritis →
Pediatric Lupus Nephritis — all drugs for Pediatric Lupus Nephritis →

Sponsor

Aurinia Pharmaceuticals Inc. — full company profile →

Who can join

Adults 5 to 17, any sex, with Adolescent Lupus Nephritis or Pediatric Lupus Nephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Systemic lupus erythematosus: pathogenesis and targeted therapy.
Su X, Yu H, Lei Q, Chen X, et al · · 2024 · cited 33× · PMID 39472388 · DOI 10.1186/s43556-024-00217-8
Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.
Natoli V, Charras A, Smith EM, Hedrich CM. · · 2025 · cited 1× · PMID 41410901 · DOI 10.1007/s11926-025-01207-7
Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.
Xu J, Zhang Y, Huang H, Cao Y. · · 2026 · PMID 42233033 · DOI 10.3389/fimmu.2026.1762892
The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.
Ciurtin C, Sparchez M, Elephtheriou D, Brogan P. · · 2025 · PMID 40845184 · DOI 10.1093/rheumatology/keaf455

Verify or expand the search:

Other Aurinia Pharmaceuticals Inc. trials

Trials by the same sponsor.

NCT05288855 — Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis · Phase 3 · terminated
NCT05337124 — A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US · completed
NCT05306379 — Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin · Phase 1 · completed
NCT04147650 — Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrom · Phase 2, PHASE3 · completed
NCT03597464 — Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05962788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aurinia Pharmaceuticals Inc.
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing